Menu
Search
|

Menu

Close
X

Genocea Biosciences Inc GNCA.OQ (NASDAQ Stock Exchange Global Market)

0.93 USD
-- (--)
As of Jun 22
chart
Previous Close 0.93
Open --
Volume --
3m Avg Volume 230,040
Today’s High --
Today’s Low --
52 Week High 6.77
52 Week Low 0.79
Shares Outstanding (mil) 28.67
Market Capitalization (mil) 50.18
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
1
EPS (USD)
FY18
-0.223
FY17
-1.983
FY16
-1.751
FY15
-1.802
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.74
Price to Sales (TTM)
vs sector
--
5.71
Price to Book (MRQ)
vs sector
2.61
5.37
Price to Cash Flow (TTM)
vs sector
--
23.32
Total Debt to Equity (MRQ)
vs sector
89.62
16.46
LT Debt to Equity (MRQ)
vs sector
56.20
12.19
Return on Investment (TTM)
vs sector
-97.45
14.38
Return on Equity (TTM)
vs sector
-127.17
16.08

EXECUTIVE LEADERSHIP

Katrine Bosley
Chairman of the Board, Since 2013
Salary: --
Bonus: --
William Clark
President, Chief Executive Officer, Director, Since 2011
Salary: $427,392.00
Bonus: --
John Bishop
Executive Vice President - Pharmaceutical Sciences, Since 2016
Salary: --
Bonus: --
Narinder Singh
Senior Vice President - Pharmaceutical Sciences and Manufacturing, Since 2018
Salary: --
Bonus: --
Jessica Flechtner
Chief Scientific Officer, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

100 Acorn Park Dr
CAMBRIDGE   MA   02140-2303

Phone: +1617.8768191

Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual's tumor.

SPONSORED STORIES